Who founded Inomagen?

Inomagen was founded by Rishi Arora in 2014.

Who are Inomagen's investors?

Inomagen's investors include Portal Innovations.

How much funding has Inomagen raised?

Inomagen has disclosed $540K raised across 3 rounds.

Where is Inomagen headquartered?

Inomagen is headquartered in Chicago, US.

Inomagen

Chicago, US · Founded 2014 · 1 known investors

Find your way into Inomagen

26 people in our graph share verified history with the Inomagen team — schools, employers, funds. One of them is your warm intro.

Josh Seamanunlockedknows Eric Sandberg · together at Generational Equity, LLC

×11knows the team · via Bradley University

Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.

Biotech Healthtech Medical Devices

Founders & leadership

Inomagen was founded in 2014 by Rishi Arora.

Rishi AroraFounder

Gerard AbateChief Medical Officer

Eric Sandberg Chief Business OfficerEric Sandberg is Chief Business Officer at Inomagen Therapeutics, a Chicago-based biotech company developing non-viral gene therapy for atrial fibrillation. He holds an MBA and engineering degree and has held commercial leadership roles at medical device and pharmaceutical companies.

Board

Marc PennBoard director

James R. VoglerBoard director

Investors · 1

Portal Innovationslisted by Portal InnovationsChicago

How we know: Portal Innovations's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$540K disclosed across 3 rounds · 2014–2025

▶$140KraisedJun 2025 · 4 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Rishi AroraExecutive Officer, Director
Marc PennDirector
James R. VoglerDirector

Offering amount: $3.8M
Amount sold: $140K
First sale: Jun 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$200KraisedApr 2024 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rishi AroraExecutive Officer, Director
James R. VoglerDirector
Marc PennDirector

Offering amount: $6.6M
Amount sold: $200K
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$200KraisedNov 2014 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rishi AroraExecutive Officer, Director

Offering amount: $400K
Amount sold: $200K
Minimum investment: $25K
First sale: Nov 2014
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Biogen Idec10 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

Regeneron NASDAQ: REGN www.regeneron.com8 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.

Orogentx6 shared keywordsOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

Companies competing with Inomagen for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Inomagen do?: Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
Who founded Inomagen?: Inomagen was founded by Rishi Arora in 2014.
Who are Inomagen's investors?: Inomagen's investors include Portal Innovations.
How much funding has Inomagen raised?: Inomagen has disclosed $540K raised across 3 rounds.
Where is Inomagen headquartered?: Inomagen is headquartered in Chicago, US.